113 / 2021-10-24 11:37:11

Fascaplysin enhanced anti-PD-1 therapy for Non-small cell lung cancer by promoting PD-L1 expression

Fascaplysin,PD-1,PD-L1,lung cancer

Lung cancer is one of the most common malignant tumors, and Non-small cell lung cancer (NSCLC) accounts for about 80% of all lung cancers. Fascaplysin, originally isolated from the Fijian sponge, has demonstrated that it exhibits broad anticancer activity as a specific CDK4 inhibitor in multiple mechanisms. In this study, we found that Fascaplysin induced apoptosis, G0/G1 cell cycle arrest, inhibited migration, decreased protein levels of molecules involved in the epithelial-mesenchymal transition phenotype, and inhibited the Wnt/β-Catenin signaling pathway in A549 cells. In addition, Fascaplysin was found to enhance anti-PD-1 therapy in NSCLC by promoting PD-L1 expression, and in vitro experimental validation revealed that Fascaplysin could up-regulate PD-L1 protein expression levels and flow cytometry revealed that the fluorescence intensity of PD-L1 was enhanced under Fascaplysin stimulation. On this basis, the effect of Fascaplysin combined with PD-L1 on the growth of mouse lung cancer xenografts was studied. Compared with the treatment, the combined treatment had a more significant inhibitory effect on the growth of transplanted tumors in mice. This may provide a theoretical basis for the clinical application of Fascaplysin combined with PD-L1 in the treatment of NSCLC.